HomeCompareTPCFF vs ABBV

TPCFF vs ABBV: Dividend Comparison 2026

TPCFF yields 571.43% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TPCFF wins by $175063.36M in total portfolio value
10 years
TPCFF
TPCFF
● Live price
571.43%
Share price
$0.35
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$175063.47M
Annual income
$130,231,186,587.70
Full TPCFF calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — TPCFF vs ABBV

📍 TPCFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTPCFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TPCFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TPCFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TPCFF
Annual income on $10K today (after 15% tax)
$48,571.43/yr
After 10yr DRIP, annual income (after tax)
$110,696,508,599.55/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, TPCFF beats the other by $110,696,486,732.67/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TPCFF + ABBV for your $10,000?

TPCFF: 50%ABBV: 50%
100% ABBV50/50100% TPCFF
Portfolio after 10yr
$87531.79M
Annual income
$65,115,606,156.71/yr
Blended yield
74.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TPCFF
No analyst data
Altman Z
8.4
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TPCFF buys
0
ABBV buys
0
No recent congressional trades found for TPCFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTPCFFABBV
Forward yield571.43%3.12%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$175063.47M$104.7K
Annual income after 10y$130,231,186,587.70$25,725.73
Total dividends collected$171282.55M$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TPCFF vs ABBV ($10,000, DRIP)

YearTPCFF PortfolioTPCFF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$67,843$57,142.86$11,559$438.51+$56.3KTPCFF
2$434,904$362,311.65$13,494$640.86+$421.4KTPCFF
3$2,635,984$2,170,637.54$15,951$945.97+$2.62MTPCFF
4$15,116,208$12,295,705.05$19,152$1,413.89+$15.10MTPCFF
5$82,071,959$65,897,616.56$23,443$2,146.38+$82.05MTPCFF
6$422,195,127$334,378,130.08$29,391$3,321.96+$422.17MTPCFF
7$2,059,328,440$1,607,579,654.60$37,948$5,265.87+$2059.29MTPCFF
8$9,531,745,742$7,328,264,311.53$50,795$8,596.74+$9531.69MTPCFF
9$41,899,326,827$31,700,358,882.77$71,034$14,549.41+$41899.26MTPCFF
10$175,063,466,293$130,231,186,587.70$104,715$25,725.73+$175063.36MTPCFF

TPCFF vs ABBV: Complete Analysis 2026

TPCFFStock

Titan Logix Corp., a technology company, engages in the research and development, manufacture, and marketing of technology fluid management solutions in Canada, the United States, and internationally. It offers mobile monitoring systems, stationery monitoring systems, and smart truck systems. The company also offers hardware, including level gauges, displays, telematics, mobile accessories, flow meters, tank scan, and transmitters. It serves oil and gas, chemical, produced water, vacuum, aviation, and fuel/lubricant industries. The company was formerly known as Titan Pacific Resources Ltd. The company was incorporated in 1979 and is headquartered in Edmonton, Canada.

Full TPCFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TPCFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TPCFF vs SCHDTPCFF vs JEPITPCFF vs OTPCFF vs KOTPCFF vs MAINTPCFF vs JNJTPCFF vs MRKTPCFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.